All In Biotech

Free tool

FAERS Monitor: Wayrilz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219685 or its brand name (Wayrilz, Rilzabrutinib). Reports on generic versions are filed under their own applications.

Reports

564

Serious

113

20% of reports

Hospitalization

83

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • platelet count decreased143
  • diarrhoea142
  • nausea105
  • drug ineffective92
  • headache52
  • fatigue50
  • product use in unapproved indication47
  • abdominal discomfort39
  • vomiting29
  • dizziness23
  • arthralgia21
  • asthenia21
  • platelet count abnormal20
  • abdominal pain upper19
  • dyspepsia16

Reports by year received

View as table
YearReports
20242
2025110
2026452

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
platelet count abnormalSignal20123.880.42,308
platelet count decreasedSignal14350.143.56,858
abdominal discomfortSignal398.76.4259
diarrhoeaSignal1428.27.1919
product use in unapproved indicationSignal477.15.4242
dyspepsiaSignal166.13.763
nauseaSignal1054.94.2340
abdominal pain upperSignal193.42.231
headacheSignal523.12.474
drug ineffectiveSignal922.62.295
fatigueSignal502.41.841
vomitingSignal292.31.620
astheniaSignal212.11.411
arthralgia211.91.28
dizziness231.71.26

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.